Allicin improves carotid artery intima-media thickness in coronary artery disease patients with hyperhomocysteinemia

Homocysteine (Hcy) is an important and independent risk factor for atherosclerotic diseases, such as coronary artery disease and ischemic cerebrovascular disease. Increased carotid artery intima-media thickness (IMT) is a non-invasive marker of systemic atherosclerosis. Allicin treatment may decreas...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2017-08, Vol.14 (2), p.1722-1726
Main Authors: Liu, De-Shan, Wang, Shu-Li, Li, Jun-Mei, Liang, Er-Shun, Yan, Ming-Zhong, Gao, Wei
Format: Article
Language:English
Subjects:
allicin
Angina pectoris
Atherosclerosis
B-mode ultrasonographic scanning
Biochemistry
Blood pressure
Cardiovascular agents
Cardiovascular disease
Carotid arteries
carotid artery intima-media thickness
Cholesterol
Complications and side effects
Coronary heart disease
Coronary vessels
Development and progression
Dosage and administration
Drug dosages
Drug therapy
Heart
Homocysteine
Hospitals
Hyperhomocysteinemia
Hypertension
Lipids
Metabolism
Oxidative stress
Risk factors
Standard deviation
Studies
Triglycerides
Ultrasonic imaging
Values
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Homocysteine (Hcy) is an important and independent risk factor for atherosclerotic diseases, such as coronary artery disease and ischemic cerebrovascular disease. Increased carotid artery intima-media thickness (IMT) is a non-invasive marker of systemic atherosclerosis. Allicin treatment may decrease serum Hcy levels and improve impaired endothelial function in rats with hyperhomocysteinemia (HHcy). The present study hypothesized that allicin has an anti-atherosclerotic effect in coronary heart disease and tested the effects of allicin treatment on carotid artery IMT and plasma Hcy levels in coronary heart disease patients with HHcy. Sixty-two coronary heart disease patients with HHcy were randomly divided into an allicin group and a control group. All patients underwent diagnostic assessment, plasma Hcy assay, blood lipid measurement and B-mode ultrasound of the carotid artery prior to and after treatment. Plasma Hcy levels were determined by high-performance liquid chromatography and fluorescence detection. Carotid artery IMT was calculated using an automated algorithm based on a validated edge-detection technique. After 12 weeks, significant decreases in carotid artery IMT, plasma Hcy levels, total cholesterol and triglycerides were observed in the allicin group (all P
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2017.4698